Canasa
Generic Name
Mesalamine
Manufacturer
AbbVie Inc. (formerly Allergan)
Country
USA
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| canasa 400 mg tablet | ৳ 5.00 | ৳ 50.00 |
Description
Overview of the medicine
Canasa (Mesalamine) 1000 mg Suppositories are used for the treatment of active mild to moderate ulcerative proctitis. Mesalamine is an anti-inflammatory drug that works locally in the bowel to reduce inflammation.
Uses & Indications
Dosage
Adults
One 1000 mg suppository rectally once daily at bedtime. For patients with a history of difficult suppository insertion, administer after a bowel movement.
Elderly
No specific dosage adjustment required, but use with caution due to potential age-related decrease in renal function.
Renal_impairment
Use with caution. Mesalamine is excreted renally; monitoring of renal function is recommended.
How to Take
Administer rectally once daily at bedtime. Remove foil wrapper. Avoid handling the suppository for too long as it will soften. Insert pointed end first into the rectum. For best results, retain the suppository for one to three hours or longer.
Mechanism of Action
Mesalamine is an aminosalicylate. Its exact mechanism of action is not fully understood, but it is believed to exert its anti-inflammatory effect locally on the colonic mucosa by inhibiting cyclooxygenase and lipoxygenase, thereby reducing the production of prostaglandins and leukotrienes, which are mediators of inflammation. It also appears to scavenge free radicals and inhibit various inflammatory cytokines.
Pharmacokinetics
Onset
Clinical improvement usually seen within 3-21 days.
Excretion
Excreted mainly in the urine, partly as parent drug and partly as metabolite. Unabsorbed drug is excreted in feces.
Half life
Plasma half-life is short, 0.5 to 1.5 hours, but the therapeutic effect is local.
Absorption
Limited systemic absorption after rectal administration (approximately 10-30% absorbed). Peak plasma concentrations occur 1-3 hours post-dose.
Metabolism
Metabolized to N-acetyl-5-aminosalicylic acid (N-Ac-5-ASA) primarily in the liver and by colonic bacteria.
Side Effects
Contraindications
- •Hypersensitivity to salicylates or any component of the suppository.
- •Severe renal or hepatic impairment.
- •Acute porphyria.
Drug Interactions
Lactulose
May interfere with mesalamine release from oral formulations, less relevant for suppositories but note general interaction.
Furosemide
Possible interaction, monitor renal function.
Azathioprine or Mercaptopurine
Increased risk of myelosuppression.
Nephrotoxic agents (e.g., NSAIDs)
Increased risk of renal adverse reactions.
Storage
Store at controlled room temperature (20-25°C or 68-77°F). Protect from excessive heat and moisture. Do not freeze.
Overdose
Overdose with mesalamine suppositories is unlikely due to limited systemic absorption. Symptoms of oral overdose may include nausea, vomiting, abdominal pain, and headache. Treatment is supportive.
Pregnancy & Lactation
Pregnancy Category B/C. Mesalamine crosses the placenta. Use during pregnancy only if clearly needed and benefits outweigh risks. Small amounts of mesalamine are excreted into breast milk. Exercise caution when administered to a nursing mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture. Refer to the specific product packaging for exact expiry.
Availability
Pharmacies, Hospitals
Approval Status
FDA Approved
Patent Status
Generic versions available, original patent expired
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
